ERBB2 and breast carcinoma: This discrepancy might be due to the use of different antibodies, criteria of evaluation and other issues related to discordant study protocols[38] and, considering the potential importance of FMCs as model for human breast cancer, a standardised method for the detection of HER2 expression and cellular localisation in feline mammary tumours is urgently needed.